Residual Embolism Evaluated With Single Photon Emission Computed Tomography (RESPECT)

August 4, 2025 updated by: Centre Hospitalier Universitaire de Saint Etienne

Residual Embolism Evaluated With Single Photon Emission Computed Tomography - The RESPECT Cohort

Major progress achieved in diagnostic and therapeutic strategies has substantially improved the short-term prognosis of patients with pulmonary embolism (PE). These improvements have led to a shift from an acute to a chronic condition of venous thromboembolism, justifying the recent development of Chronic Thrombo-embolic Disease (CTED). In most of the situations, it is due to a residual pulmonary vascular obstruction (RPVO) which can be assessed by pulmonary scintigraphy.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Planar ventilation/perfusion (V/Q) scintigraphy is the gold standard, but for several months, V/Q single photon emission computed tomography (SPECT) is recommended in the guidelines.

The aim of this study is to evaluate the performances of various SPECT protocols to quantified RPVO and compared to planar scintigraphy to evaluate the RPVO.

Study Type

Observational

Enrollment (Estimated)

358

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
      • Saint-Étienne, France, 42055
        • Recruiting
        • Centre Hospitalier Universitaire
        • Principal Investigator:
          • Pierre-Benoit BONNEFOY, MD
        • Sub-Investigator:
          • Nathalie PREVOT, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with V/Q pulmonary SPECT-CT assess to rule out perfusion obstruction, patients admitted for a suspicion of PH, or a persistent dyspnea after PE

Description

Inclusion Criteria:

  • Patient addressed to nuclear medicine department of Saint-Etienne public hospital for V/Q pulmonary SPECT-CT assess to rule out perfusion obstruction, admitted for a suspicion of pulmonary hypertension (PH), or a persistent dyspnea after PE
  • Patient affiliated ou beneficiary of social security.

Exclusion Criteria:

  • Pregnant patient.
  • Patient addressed to nuclear medicine department for acute pulmonary embolism.
  • Impossibility of the entire protocol acquisitions realization.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
RPVO (%)
Time Frame: At inclusion
Evaluation of the RPVO establish with Meyer score (planar scintigraphy, 2D). The higher the percentage, the greater the obstruction of the lung
At inclusion
Segmental visual score
Time Frame: At inclusion
Evaluation of segmental visual score (SPECT-CT , 3D) The higher the percentage, the greater the obstruction of the lung
At inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de Saint Etienne

Investigators

  • Principal Investigator: Pierre-Benoit BONNEFOY, MD, CENTRE HOSPITALIER DE SAINT-ETIENNE

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 27, 2024

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

April 1, 2026

Study Registration Dates

First Submitted

June 19, 2024

First Submitted That Met QC Criteria

June 19, 2024

First Posted (Actual)

June 25, 2024

Study Record Updates

Last Update Posted (Actual)

August 7, 2025

Last Update Submitted That Met QC Criteria

August 4, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 23CH190
  • 2024-A00613-44 (Other Identifier: ANSM)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Circulation Obstruction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe